This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q78.1 (polyostotic fibrous dysplasia) | Special Copayment Reduction: V154 (rare disease) |
| B. Synonyms | Polyostotic fibrous dysplasia | Albright(-McCune)(-Sternberg) syndrome |
| C. Adult onset | Likelihood of first onset in adulthood: low to moderate — bone lesions and skin spots are usually found in childhood, but if symptoms are mild they are sometimes found incidentally in adulthood; endocrine complications (hyperparathyroidism, thyroid nodules, acromegaly) may appear in adulthood; pain and deformity due to bone lesions also progress in adults. |
| 1. History | 1937 independent descriptions by McCune and Albright → triad (bone lesions, skin spots, precocious puberty) → 1988 Weinstein identified GNAS mosaic mutations → understanding of the monostotic to polyostotic and MAS spectrum established. |
| 2. Causes | Somatic mosaic gain-of-function mutation of the GNAS gene (20q13.32) early in embryonic development (mainly Arg201His or Arg201Cys). Overactivation of cAMP signaling causes abnormal proliferation of osteoblast progenitor cells and autonomous activation of endocrine glands. Germline mutations have not been reported (lethal). |
| 3. Genetics | GNAS gene: 20q13.32, encodes Gsα (stimulatory G protein α subunit). Somatic mosaic mutation → non-hereditary (not transmitted to children). The timing of mutation (the earlier in the embryo, the more extensive the involvement) determines phenotypic diversity. Spectrum from monostotic FD to the McCune-Albright triad. |
| 4. General epidemiology | Prevalence of monostotic fibrous dysplasia about 1/4,000~1/10,000. Polyostotic (PFD): about 1/100,000. McCune-Albright syndrome (MAS): about 1/100,000~1/1,000,000. Polyostotic about 30% of all FD. MAS more frequent in females (especially with precocious puberty). |
| 5. Pathophysiology | Constitutive GNAS Gsα activation → cAMP overproduction → overactivation of the PKA pathway → abnormal proliferation and differentiation of osteoblast progenitor cells, formation of fibrous matrix and immature bone tissue instead of normal bone matrix. Autonomous hyperfunction in endocrine glands (thyroid, adrenal, gonads). Outside the skeleton, overactivity of skin melanocytes forms café-au-lait spots. |
| 6. Symptoms | Bone: pain, fractures, deformity (including shepherd's crook deformity), cranial nerve compression (blindness, hearing loss). Skin: café-au-lait spots (irregular borders). Endocrine: precocious puberty (mainly ovarian cysts in girls), hyperthyroidism and nodules, GH excess (acromegaly), hypophosphatemic rickets due to FGF23 excess. |
| 7. Signs | X-ray: ground-glass opacity, cortical expansion and thinning. Skull overgrowth, shepherd's crook deformity of the proximal femur. Café-au-lait spots (coastline borders). Decreased bone density on DXA. Abnormal endocrine function tests. |
| 8. Screening | No screening of the general population. When clinically suspected: whole-body skeletal scan (99mTc bone scan) + X-ray and CT of target sites. MAS suspected when the combination of café-au-lait spots + endocrine abnormalities is found. GNAS somatic mutation analysis (ddPCR or NGS based on lesional tissue). |
| 9. Diagnosis | Clinical diagnosis possible when the clinical triad (bone lesions, café-au-lait spots, precocious puberty) is met. Confirmation: GNAS mutation analysis of lesional tissue (bone or skin). Imaging: whole-body bone scan, CT (skull, face), MRI (skull base, spinal cord compression). Endocrine function tests (FSH, LH, estradiol, GH, IGF-1, thyroid, serum phosphate). Tissue biopsy (confirmation of ground-glass lesions). |
| 10. Treatment | Bone: bisphosphonates (pamidronate, zoledronate) reduce bone pain and fractures. Surgical fixation for fractures. Cranial nerve decompression. Precocious puberty: aromatase inhibitors (letrozole), SERMs (tamoxifen). GH excess: octreotide, pegvisomant. Hypophosphatemia: oral phosphate, active vitamin D. Thyroid: medication or surgery. |
| 11. Prognosis | Bone lesions tend to stabilize after puberty. Complications of cranial nerve compression can cause permanent disability. Risk of osteosarcoma transformation about 0.5% (relatively low, but risk increases after radiation therapy). Quality of life can be managed with individual treatment of endocrine complications. Life expectancy close to normal without complications. |
| 12. Prevention | Non-hereditary disease, so primary prevention is not possible. Early detection of complications through regular whole-body bone scans and endocrine evaluation. Radiation therapy contraindicated (risk of malignant transformation). Prophylactic surgical fixation of sites at risk of fracture considered. Prevention of bone pain and fractures by early initiation of bisphosphonates. |
| 13. References | Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol. 2008 … and 9 other papers |
The history of polyostotic fibrous dysplasia and McCune-Albright Syndrome (MAS) dates back to the 1930s. In 1937, the American pediatrician Donovan James McCune first reported a girl with café-au-lait macules of the skin, early sexual maturation (precocious puberty), and multiple skeletal lesions. In the same year, the internist Fuller Albright, together with colleagues, reported a similar group of cases and proposed that these three findings constitute a single syndrome, emphasizing the replacement of bone lesions by fibrous tissue. Thereafter, this complex clinical presentation came to be called 'Albright-McCune-Sternberg syndrome', after three people, or 'McCune-Albright syndrome'.
The skeletal dysplasia itself was recognized much earlier. In 1891, Friedrich von Recklinghausen of Germany described osteitis fibrosa disseminata, and subsequently Braitsev and Louis Lichtenstein, over 1938~1942, defined monostotic and polyostotic fibrous dysplasia as an independent clinical entity and established the name 'fibrous dysplasia (FD)'. The 1942 classification by Lichtenstein and Jaffe became the starting point of the modern understanding.
The turning point in elucidating the molecular mechanism was the report in 1988 by Michael Weinstein and Allen Spiegel of the US NIH that somatic activating mutations of the GNAS gene cause MAS. This discovery holds an important place in medical history as the first case elucidating the oncogenic role of the G protein signaling system. Subsequently, in 1991, Lacruz et al. confirmed that the Arg201His mutation is the most common variant, and the theory was established that the somatic mosaic nature of GNAS mutations — that is, the mutation arises in a specific cell early in embryonic development and is transmitted only to its descendant cells — explains the diversity of phenotypes.
In the 2000s, large cohort studies on the long-term natural history, endocrine complications, and risk of malignant transformation of fibrous dysplasia and MAS were conducted, centered on the US NIH and European centers. The effect of bisphosphonates (especially pamidronate) in reducing bone pain and fractures was verified in clinical trials, and aromatase inhibitors became standard for treating precocious puberty associated with MAS. Since the 2010s, preclinical research and early clinical trials of next-generation therapies targeting downstream of the GNAS signaling pathway (MEK inhibitors, etc.) have been under way, opening new therapeutic horizons.
The cause of polyostotic fibrous dysplasia and McCune-Albright syndrome is a somatic gain-of-function mutation of the GNAS gene (20q13.32). The GNAS gene encodes the stimulatory G protein alpha subunit (Gsα), and this protein regulates intracellular cAMP production as a signal transducer between cell surface receptors and adenylyl cyclase.
Pathogenic mutations are mainly the amino acid substitutions Arg201His (R201H) or Arg201Cys (R201C), and Gln227Leu/Arg and others are rarely reported. Arg201 is a residue essential for the GTPase activity of Gsα, and mutations at this position abolish intrinsic GTPase activity, so Gsα remains continuously in the GTP-bound state. As a result, adenylyl cyclase is continuously activated and intracellular cAMP levels rise markedly.
The most clinically important characteristic is that this mutation occurs only in somatic mosaic form. That is, after the mutation arises in a specific cell early in embryonic development, it is transmitted only to its descendant cells (clone), so only some cells in the body carry the mutation and the rest are normal. Germline GNAS mutations (present in all cells) are known to be lethal, making fetal survival impossible, and therefore MAS is a non-hereditary disease that is not transmitted to children.
The diversity of phenotypes — the spectrum from monostotic FD to polyostotic FD to complete MAS — is determined by the time during embryonic development at which the mutation arose and the types of tissue in which the mutant cell clone is distributed. If the mutation arises very early in embryonic development, mutant cells are distributed in more tissues, showing extensive skeletal involvement and multiple endocrine abnormalities (MAS). Conversely, if the mutation arises later in development, only limited tissues are involved, showing the monostotic or partially polyostotic FD form.
The GNAS gene is located on the long arm of chromosome 20 (20q13.32) and is a complex gene encoding multiple proteins (Gsα, XLαs, NESP55, A/B transcripts, etc.) through several alternative promoters and first exons. Of these, the one at issue in fibrous dysplasia and MAS is the Gsα-coding transcript, which consists of exons 1-13 (the standard coding sequence).
The GNAS gene region is also subject to genomic imprinting. From the maternal allele, Gsα is predominantly expressed in some tissues (especially the renal proximal tubule), and from the paternal allele, alternative transcripts (XLαs, etc.) are expressed. This imprinting pattern influences the manifestations of various GNAS-related diseases (pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, etc.). However, whether maternal or paternal origin matters in the development of FD/MAS has not yet been clearly established.
Because it is a somatic mosaic mutation, the mutation fraction is often too low to be detected by standard blood DNA analysis. Mutation detection requires digital droplet PCR (ddPCR) or high-sensitivity NGS techniques on DNA extracted from lesional tissue (bone tissue or cells within FD lesions). Detection of the mutation in peripheral blood DNA means that mutant cells are also distributed in the hematopoietic system, which in this case suggests more extensive involvement. Even if genetic testing is negative, a clinical diagnosis is possible if the MAS is clinically typical.
Because FD/MAS is not transmitted to children, family history review and genetic counseling are conducted to assess the patient's own risk of recurrence or possibility of other organ involvement and to provide psychological support. Because it is a new somatic mutation, the risk to siblings is not increased either.
Fibrous dysplasia (FD) is divided into monostotic and polyostotic forms, and the overall prevalence is estimated at about 1/4,000~1/10,000 on a monostotic basis. Of all FD, monostotic accounts for about 70% and polyostotic for about 30%. The prevalence of polyostotic FD is about 1/100,000, and complete MAS is very rare at about 1/100,000~1/1,000,000.
FD occurs in both sexes, but the typical triad of MAS (precocious puberty, café-au-lait spots, bone lesions) is reported much more commonly in girls. This is because precocious puberty due to LH-independent ovarian cysts is prominent in girls, whereas in boys testis-independent precocious puberty is relatively rare, so diagnosis may be delayed. The most common sites of involvement in monostotic FD are the craniofacial bones (about 25%) and the femur and tibia (about 50%), and in polyostotic FD multiple sites such as the lower limb bones, craniofacial bones, ribs, and pelvic bones are involved.
FD bone lesions progress most actively in childhood and adolescence, and after puberty they tend to stabilize as the growth plates close under the influence of estrogen and androgen. However, in some patients lesions progress or new fractures occur even in adulthood. Malignant transformation (mainly osteosarcoma) is very low at about 0.5% of all FD patients, but the risk increases markedly at sites that previously received radiation therapy (radiation therapy is now contraindicated).
Worldwide, FD/MAS patient registries and natural history studies are conducted centered on the US NIH, the European Reference Networks (ERN), and the International FD/MAS Alliance. In Korea, medical expense reduction benefits are provided upon registration under the rare disease special copayment reduction (V154).
The core pathophysiology of polyostotic fibrous dysplasia is persistent overactivation of the cAMP signaling pathway due to activating GNAS Gsα mutations. Normally, when hormone receptors (PTHR, LH receptor, TSH receptor, etc.) are engaged, Gsα binds GTP and activates adenylyl cyclase to produce cAMP, then inactivates itself through its intrinsic GTPase activity.
In Arg201 mutations, this self-inactivation mechanism is lost, so Gsα remains continuously in the activated state and adenylyl cyclase produces cAMP incessantly. In the skeleton, excess cAMP persistently activates protein kinase A (PKA), which, through phosphorylation of the transcription factor CREB, promotes proliferation of osteoblast progenitor cells (osteoprogenitors) and inhibits normal differentiation. As a result, immature stromal cells that fail to differentiate into mature osteoblasts accumulate, and these cells produce fibrous stroma and disorganized fragments of woven bone instead of normal lamellar bone. This is the histological basis of the 'ground-glass' opacity seen on imaging.
FGF23 overproduction: cells within the lesions oversecrete FGF23, which inhibits renal phosphate reabsorption and impairs 1,25-OH vitamin D activation, resulting in hypophosphatemia and rickets/osteomalacia. This is the main cause of the bone mineralization abnormalities seen in patients with extensive polyostotic FD.
In the endocrine system, persistent Gsα activation causes endocrine glands to secrete hormones autonomously even without hormonal stimulation. Autonomous estrogen secretion from ovarian cysts causes precocious puberty in girls; in the thyroid, TSH-independent hyperthyroidism appears; in the adrenal cortex, Cushing syndrome; and in pituitary GH-secreting cells, acromegaly and gigantism occur. In skin melanocytes, excess cAMP promotes melanin synthesis, forming café-au-lait spots.
The clinical symptoms of polyostotic fibrous dysplasia and MAS are broadly divided into skeletal lesions, skin lesions, and endocrine abnormalities, and the extent and degree of involvement in each area vary greatly from patient to patient.
Skeletal symptoms: the most common symptom in polyostotic FD is bone pain, appearing mainly in the lower limbs (femur, tibia) and craniofacial bones. Pathological fractures due to low-energy trauma may recur, and cumulative fractures and bone softening in the proximal femur form the characteristic shepherd's crook deformity, causing severe gait impairment. With craniofacial involvement, facial asymmetry and lion-face (leontiasis ossea) deformity appear, and narrowing of the optic canal and auditory canal can cause vision loss and hearing loss. Nerve compression in skull base FD is one of the most serious complications.
Skin symptoms: café-au-lait macules are characterized by irregular borders (coastline-like, coast of Maine) and are distinguished from the regular borders (coast of California) of neurofibromatosis type 1. The spots are usually distributed preferentially on one side of the trunk and tend to be located on the same side as the bone lesions. Size and number vary, and they appear from early infancy.
Endocrine symptoms: in girls, gonadotropin-independent precocious puberty (GnRH-independent precocious puberty) is the most common endocrine abnormality. Breast development, vaginal bleeding, and pubic hair development may appear before age 2, because estrogen is secreted autonomously from functional ovarian cysts. Thyroid abnormalities (nodular goiter, hyperthyroidism) are the second most common endocrine complication. Gigantism and acromegaly due to growth hormone (GH) excess are also not uncommon, and this has an important effect on prognosis. Hypophosphatemic osteomalacia and rickets due to FGF23 excess accompany in patients with extensive bone involvement, adding to fracture risk. Cushing syndrome (autonomous adrenocortical activity), when it appears in the neonatal period, is very serious and can be life-threatening.
The physical and radiological signs of polyostotic fibrous dysplasia and MAS vary depending on the site of involvement and severity.
Physical signs: café-au-lait spots are brown hyperpigmented macules with irregular borders (coast of Maine-like) distributed unilaterally on the skin and can be observed with the naked eye. Shepherd's crook deformity of the proximal femur is identified on examination by gait abnormality and limb shortening. Facial asymmetry, ptosis, proptosis, and limited mouth opening due to craniofacial bone overgrowth may be observed. In girls, breast development, pubic hair, and vaginal bleeding before age 2 suggest precocious puberty.
Radiological signs: on plain X-ray, the most characteristic feature of FD lesions is ground-glass opacity, appearing as the medullary cavity is replaced by fibrous stroma. The cortical bone expands and thins, and a sclerotic rim may form within or around the lesion. In the proximal femur, shepherd's crook deformity is clearly seen on X-ray. Skull CT evaluates skull base overgrowth, narrowing of neural canals (optic canal, internal auditory canal), and craniofacial bone deformity. 99mTc whole-body bone scan is the most useful imaging tool for simultaneously evaluating all involved skeletal sites, showing intense radioisotope uptake in FD lesions. MRI evaluates soft tissue involvement, skull base nerve compression, and spinal cord involvement.
Endocrine laboratory signs: in precocious puberty, elevated serum estradiol with suppressed or low-responding LH and FSH (GnRH-independent); in hyperthyroidism, elevated free T4 and suppressed TSH; in GH excess, elevated serum GH and IGF-1 (poor GH suppression with glucose load); in FGF23 excess, low serum phosphate, increased urinary phosphate loss, and elevated alkaline phosphatase are observed. On DXA, a difference between decreased bone density in the involved skeleton and normal bone density in uninvolved sites may appear.
Histological signs: in lesional tissue, fragments of woven bone (woven bone trabecules) within fibrous stroma, irregularly arranged trabeculae, absence or reduction of normal osteoclasts and osteoblasts, and a 'Chinese writing' bone pattern are characteristic.
Universal screening of the general population is not performed for polyostotic fibrous dysplasia and MAS. Because it is a non-hereditary disease caused by a somatic mosaic mutation, family history-based screening does not apply either. Clinical suspicion is the key to screening.
Criteria for clinical suspicion: FD/MAS is suspected and systematic evaluation is started when one or more of the following are present. ① Unexplained bone pain or pathological fractures in childhood; ② café-au-lait spots (especially with irregular borders and unilateral distribution); ③ early sexual development (breasts, pubic hair, vaginal bleeding) before age 2~8; ④ craniofacial asymmetry or proptosis; ⑤ the combination of hypophosphatemia and elevated alkaline phosphatase; ⑥ ground-glass bone lesions found incidentally on imaging.
Whole-body skeletal scan: when FD is clinically suspected, a 99mTc whole-body bone scan is performed to determine whether involvement is monostotic or polyostotic and the number of involved sites. This provides a baseline for treatment planning and monitoring of complications. Lesions are then evaluated in detail with X-ray or CT of the target sites.
Endocrine function screening: when polyostotic FD or MAS is suspected, a comprehensive endocrine evaluation including thyroid function (TSH, free T4), serum GH and IGF-1, serum phosphate and FGF23, adrenocortical function (cortisol), and sex hormones (estradiol or testosterone, LH, FSH) is recommended. This allows early detection of asymptomatic endocrine complications.
Molecular diagnosis: for GNAS somatic mutation analysis, ddPCR or deep amplicon NGS based on lesional tissue (bone tissue or FD lesion cells) is the most sensitive. Detection of the mutation in peripheral blood DNA suggests extensive involvement. When the clinical diagnosis is clear, molecular diagnosis may not necessarily be required, but it is important for differential diagnosis in atypical cases.
The diagnosis of polyostotic fibrous dysplasia and MAS is made by integrating clinical findings, imaging, tissue biopsy, and molecular genetic analysis. When all elements of the typical MAS triad (polyostotic FD + café-au-lait spots + GnRH-independent precocious puberty) are met, a clinical diagnosis is possible. In atypical cases or monostotic FD, molecular diagnosis is important.
Imaging diagnosis: plain X-ray evaluates the ground-glass opacity of FD lesions, cortical expansion, and fractures. CT is essential for detailed structural analysis of the craniofacial bones and skull base and is used to assess the degree of neural canal narrowing and for surgical planning. MRI is used to evaluate intracranial and spinal nerve compression, soft tissue changes, and bone marrow involvement. 99mTc whole-body bone scan is the most useful tool for evaluating the involved sites as a whole. PET-CT is used as an adjunct when malignant transformation is suspected.
Tissue biopsy: bone biopsy is needed when the diagnosis is unclear or malignant transformation must be excluded. Characteristic histological findings are fragments of woven bone within fibrous stroma, a 'Chinese writing' bone pattern, and loss of normal bone architecture. GNAS mutation analysis can also be performed on the biopsy tissue at the same time.
Endocrine function tests: a comprehensive endocrine evaluation is performed, including thyroid function (TSH, free T4), serum IGF-1 and GH (OGTT suppression test), serum phosphate, FGF23, and ALP, sex hormones (LH, FSH, estradiol or testosterone), 24-hour urinary cortisol (when Cushing syndrome is suspected), and parathyroid hormone (to differentiate parathyroid dysfunction). To evaluate precocious puberty, an LH/FSH GnRH stimulation test and bone age measurement are needed.
Bone density and bone turnover markers: bone density of the lumbar spine, hip, and whole body is measured by DXA, comparing involved and uninvolved sites. Serum ALP (total ALP and bone-specific ALP), P1NP, CTX, serum phosphate and FGF23, and 25-OH vitamin D are measured to assess bone metabolic status and treatment response.
Hearing and vision assessment: in patients with craniofacial or skull base involvement, regular pure-tone audiometry and ophthalmologic examination (visual acuity, visual field, fundus, intraocular pressure) are essential. When optic canal compression is suspected, immediate CT/MRI evaluation and ophthalmology consultation are needed.
Treatment of polyostotic fibrous dysplasia and MAS consists of management of skeletal complications, treatment of endocrine abnormalities, and surgical management of nerve compression complications, and requires a multidisciplinary approach tailored to each patient's sites of involvement and pattern of complications.
Bisphosphonates: intravenous pamidronate has been confirmed in clinical trials to be effective in reducing FD-related bone pain and fracture frequency. Improvement in pain scores and increased bone density have been reported, and it is administered repeatedly every 6 months. Zoledronate, given 1~2 times a year, is convenient and used in adults. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and the metabolic turnover of the fibrous matrix. Bone pain is the main indication, and use in asymptomatic bone lesions takes individual risk-benefit into account.
Treatment of precocious puberty: because the precocious puberty is GnRH-independent (peripheral), GnRH agonists are ineffective. Aromatase inhibitors (letrozole, anastrozole) are effective in suppressing estrogen production and halting the progression of precocious puberty. SERMs (tamoxifen, raloxifene) are estrogen receptor antagonists used as adjuncts in MAS precocious puberty. Surgical management may be needed for acute bleeding or torsion due to ovarian cysts.
Treatment of GH excess: somatostatin analogs (octreotide, lanreotide) are used to suppress GH secretion and normalize IGF-1. A GH receptor antagonist (pegvisomant) is used when the response to somatostatin analogs is insufficient. Because GH excess accelerates the progression of FD bone lesions, early treatment is important.
Treatment of hypophosphatemia: oral phosphate supplements and active vitamin D (calcitriol or alfacalcidol) are the basis of treatment for hypophosphatemic osteomalacia due to FGF23 excess. An anti-FGF23 antibody (burosumab) targeting FGF23 itself has been approved for X-linked hypophosphatemia, and studies of its use in FD-related hypophosphatemia are in progress.
Surgical treatment: prophylactic or therapeutic intramedullary rod insertion is needed in femurs with shepherd's crook deformity or recurrent fractures. The timing of nerve decompression surgery for nerve compression due to craniofacial bone overgrowth (especially of the optic and auditory nerves) is controversial, and immediate intervention is needed when symptomatic vision loss or visual field defects worsen. Skull base surgery is high-risk surgery performed at specialized centers.
Radiation therapy contraindicated: radiation therapy to FD lesions is absolutely contraindicated because it markedly increases the risk of malignant transformation (osteosarcoma).
The prognosis of polyostotic fibrous dysplasia and MAS varies greatly depending on the extent of skeletal involvement, the type and severity of endocrine complications, and whether cranial nerve compression complications occur.
Skeletal prognosis: bone lesions progress most actively in childhood to adolescence and mostly stabilize on entering adulthood. However, once shepherd's crook deformity of the proximal femur is established, gait impairment may remain permanently. Bisphosphonate treatment reduces bone pain and fracture frequency, but meaningful changes in imaging findings are limited. In patients with extensive polyostotic FD (involvement of 50% or more of the whole skeleton), hypophosphatemia, severe skeletal deformity, and cranial nerve compression combine to markedly reduce quality of life.
Malignant transformation: the risk of malignant transformation in all FD patients is low at about 0.5%. However, with a history of prior radiation therapy, the risk increases dozens of times. Malignant transformation is mainly osteosarcoma and usually arises within existing FD lesions in adults. Rapid worsening of existing bone pain, rapid lesion growth, and formation of a soft tissue mass are warning signs of malignant transformation.
Cranial nerve complications: vision loss due to optic canal compression can be partially recovered with decompression if detected early, but in advanced cases may result in permanent blindness. Hearing loss results from involvement of the ossicles and internal auditory canal and can be partly corrected with hearing aids.
Prognosis of endocrine complications: with early detection and appropriate treatment, long-term sequelae of endocrine complications such as precocious puberty, GH excess, and hyperthyroidism can be minimized. Neonatal Cushing syndrome can be life-threatening and requires immediate management. Life expectancy does not differ greatly from that of the general population in the absence of cranial nerve complications and serious endocrine complications.
Because polyostotic fibrous dysplasia and MAS are caused by somatic mosaic mutations, genetic prevention is not possible, and because they are not transmitted to children, family-based prevention does not apply either.
Early detection of complications: after diagnosis, asymptomatic complications are detected early through regular whole-body bone scans (every 2~3 years), craniofacial CT, and endocrine function tests. Immediate evaluation is needed when symptoms of cranial nerve compression (changes in vision, changes in hearing, headache) occur. With endocrine complications such as precocious puberty and GH excess, early treatment can minimize sequelae for growth and development.
Education on the contraindication to radiation therapy: patients, caregivers, and the attending medical team are educated that radiation therapy to FD lesions is absolutely contraindicated, to prevent situations in which radiation therapy is prescribed at another institution.
Fracture prevention: when signs of fracture appear at high-risk sites such as the proximal femur, prophylactic surgery (rod insertion) is performed early to prevent complete fracture and the formation of shepherd's crook deformity. Fall-prevention education, strengthening through physical therapy, and the use of assistive devices help reduce fall-related fractures.
Prophylactic use of bisphosphonates: when symptomatic bone pain or sites at high risk of fracture are identified, bisphosphonates are used prophylactically to lower fracture frequency. Adequate calcium and vitamin D intake, and phosphate supplementation when FGF23 excess is present, are given concurrently. Regular follow-up by a multidisciplinary specialist team (endocrinology, orthopedics, ophthalmology, neurosurgery, rehabilitation medicine) is key to managing complications.
Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol. 2008;22(1):55-69. DOI: 10.1016/j.berh.2007.11.009. PMID: 18328975.
Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3:12. DOI: 10.1186/1750-1172-3-12. PMID: 18489744.
Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688-1695. DOI: 10.1056/NEJM199112123252403. PMID: 1944469.
Leet AI, Collins MT. Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. J Child Orthop. 2007;1(1):3-17. DOI: 10.1007/s11832-007-0006-4. PMID: 19308499.
Boyce AM, Burke A, Cutler Peck C, et al. Surgical management of polyostotic craniofacial fibrous dysplasia: long-term outcomes and predictors for postoperative regrowth. Plast Reconstr Surg. 2016;137(6):1833-1839. DOI: 10.1097/PRS.0000000000002112. PMID: 27219247.
Matarazzo P, Lala R, Moshang T, et al. Bisphosphonate treatment in childhood and adolescence: an ovarian function evaluation in young adult patients affected by polyostotic fibrous dysplasia or osteogenesis imperfecta. J Endocrinol Invest. 2004;27(5):446-451. PMID: 15279064.
Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab. 2007;92(6):2100-2106. DOI: 10.1210/jc.2006-2061. PMID: 17374706.
Boyce AM, Chong WH, Shawker TH, et al. Characterization and management of testicular pathology in McCune-Albright syndrome. J Clin Endocrinol Metab. 2012;97(9):E1782-E1790. DOI: 10.1210/jc.2012-1791. PMID: 22760054.
Riminucci M, Robey PG, Bianco P. The pathology of fibrous dysplasia and the McCune-Albright syndrome. Pediatr Endocrinol Rev. 2007;4(Suppl 4):401-411. PMID: 17982416.
Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 2012;7(Suppl 1):S4. DOI: 10.1186/1750-1172-7-S1-S4. PMID: 22640971.